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Abstract: Importance: Therapeutic options for patients with secondary progressive multiple sclerosis
(SPMS) are limited. Objective: To analyze disability progression in patients with SPMS treated with
rituximab compared with matched control patients never treated with rituximab. Design, Setting, and
Participants: This retrospective cohort study analyzed data obtained from patients with SPMS at 3
multiple sclerosis centers located in Basel and Lugano, Switzerland, and Amsterdam, the Netherlands,
from 2004 to 2017. Patients were included for analysis if they had received a diagnosis of SPMS, were
treated (57 eligible; 54 included) or never treated (504 eligible; 59 included) with rituximab, and had
at least 1 follow-up visit. The variables used for propensity score matching were sex, age, Expanded
Disability Status Scale (EDSS) score, and disease duration. Follow-up duration was up to 10 years,
with a mean (SD) of 3.5 (2.6) years for rituximab-treated patients and 5.4 (2.4) years for controls in
the total cohort and a mean (SD) of 3.5 (2.7) years for rituximab-treated patients and 4.8 (2.2) years
for controls in the matched cohort. Exposures: Comparing EDSS score progression in patients with
SPMS (treated with rituximab vs not treated with rituximab) using propensity score matching. Main
Outcomes and Measures: The primary end point was progression of EDSS score after baseline, and the
secondary end point was time to confirmed disability progression. Results: After 1:1 propensity score
matching, 44 matched pairs (88 patients) were included in the analysis. At baseline, patients treated
with rituximab had a mean (SD) age of 49.7 (10.0) years, mean (SD) disease duration of 18.2 (9.4) years,
and mean (SD) EDSS score of 5.9 (1.4), and 26 (59%) were women, whereas controls had a mean (SD)
age of 51.3 (7.4) years, mean (SD) disease duration of 19.4 (8.7) years, and mean (SD) EDSS score of
5.70 (1.29), and 27 (61%) were women. In the covariate-adjusted analysis of the matched set, patients
with SPMS who were treated with rituximab had a significantly lower EDSS score during a mean (SD)
follow-up of 3.5 (2.7) years (mean difference, -0.52; 95% CI, -0.79 to -0.26; P < .001). Time to confirmed
disability progression was significantly delayed in the rituximab-treated group (hazard ratio, 0.49; 95%
CI, 0.26-0.93; P = .03). Conclusions and Relevance: In this study, patients with SPMS treated with
rituximab had a significantly lower EDSS score for up to 10 years of follow-up and a significantly delayed
confirmed progression compared with matched controls, suggesting that B-cell depletion by rituximab
may be therapeutically beneficial in these patients. A prospective randomized clinical trial with a better
level of evidence is needed to confirm the efficacy of rituximab in such patients.
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IMPORTANCE Therapeutic options for patients with secondary progressive multiple sclerosis
(SPMS) are limited.
OBJECTIVE To analyze disability progression in patients with SPMS treated with rituximab
compared with matched control patients never treated with rituximab.
DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study analyzed data obtained
from patients with SPMS at 3multiple sclerosis centers located in Basel and Lugano,
Switzerland, and Amsterdam, the Netherlands, from 2004 to 2017. Patients were included
for analysis if they had received a diagnosis of SPMS, were treated (57 eligible; 54 included) or
never treated (504 eligible; 59 included) with rituximab, and had at least 1 follow-up visit. The
variables used for propensity score matching were sex, age, Expanded Disability Status Scale
(EDSS) score, and disease duration. Follow-up duration was up to 10 years, with a mean (SD)
of 3.5 (2.6) years for rituximab-treated patients and 5.4 (2.4) years for controls in the total
cohort and amean (SD) of 3.5 (2.7) years for rituximab-treated patients and 4.8 (2.2) years for
controls in thematched cohort.
EXPOSURES Comparing EDSS score progression in patients with SPMS (treated with
rituximab vs not treated with rituximab) using propensity score matching.
MAIN OUTCOMES ANDMEASURES The primary end point was progression of EDSS score after
baseline, and the secondary end point was time to confirmed disability progression.
RESULTS After 1:1 propensity score matching, 44matched pairs (88 patients) were included
in the analysis. At baseline, patients treated with rituximab had amean (SD) age of 49.7 (10.0)
years, mean (SD) disease duration of 18.2 (9.4) years, andmean (SD) EDSS score of 5.9 (1.4),
and 26 (59%) were women, whereas controls had amean (SD) age of 51.3 (7.4) years, mean
(SD) disease duration of 19.4 (8.7) years, andmean (SD) EDSS score of 5.70 (1.29), and 27
(61%) were women. In the covariate-adjusted analysis of thematched set, patients with
SPMSwhowere treated with rituximab had a significantly lower EDSS score during a mean
(SD) follow-up of 3.5 (2.7) years (mean difference, −0.52; 95% CI, −0.79 to −0.26; P < .001).
Time to confirmed disability progression was significantly delayed in the rituximab-treated
group (hazard ratio, 0.49; 95% CI, 0.26-0.93; P = .03).
CONCLUSIONS AND RELEVANCE In this study, patients with SPMS treated with rituximab had a
significantly lower EDSS score for up to 10 years of follow-up and a significantly delayed
confirmed progression compared with matched controls, suggesting that B-cell depletion by
rituximabmay be therapeutically beneficial in these patients. A prospective randomized
clinical trial with a better level of evidence is needed to confirm the efficacy of rituximab in
such patients.
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M
ultiple sclerosis (MS) is a chronic inflammatory de-
myelinating disease of the central nervous system
(CNS).1 The majority of patients present with a re-
lapsing-remitting (RRMS) courseofdisease, followedbyapro-
gressivephase termedsecondaryprogressiveMS(SPMS).2Cur-
rent disease-modifying treatments target the inflammatory
pathology and only indirectly the neurodegenerative pathol-
ogy of the disease, and their therapeutic effects in (second-
ary) progressive MS have been very limited.
Data from animal models, human neuropathologic stud-
ies, and clinical trials suggest a prominent role for B cells in
thepathogenesis ofMS, both inRRMSandSPMS.Theprogres-
sive phase is characterized by a compartmentalized inflam-
matory process that persists beyond a relatively intact blood-
brain barrier. B-cell follicle-like structures are found in the
meninges as a correlate of this CNS restricted inflammation.1,3
Potential drugs for progressive forms of MS should, there-
fore, be able topass theblood-brainbarrier and shouldbe able
to target proinflammatory mediators and mechanisms di-
rectly in the brain or should influence the immune axis be-
tween the peripheral immune system and the CNS.3 Recent
studies postulate that there is a B-cell exchange across the
blood-brain barrier. Rituximab, a monoclonal CD20 anti-
body,mightaffect theB-cellpopulationwithintheCNSthrough
depletion of the peripheral B-cell compartment.4,5 Ritux-
imab is detectable in low concentrations within cerebrospi-
nal fluid after intravenous administration, opening the possi-
bility of a direct effect on CNS resident B cells.6
In a phase 2 trial, rituximab reduced clinical activity and
inflammatory brain lesions in RRMS.7 Another trial tested ri-
tuximab in primary progressivemultiple sclerosis (PPMS).8A
posthocanalysis showedthat rituximabaffecteddisabilitypro-
gression in patients of younger age and those with contrast-
enhancing lesions.
More recently the humanizedmonoclonal anti-CD20 an-
tibodyocrelizumabsignificantly reduced thepercentageofpa-
tients with confirmed disability progression (CDP) compared
with interferonbeta-1a inRRMSandsignificantly reducedCDP
comparedwithplacebo inPPMS.9,10 In 2014, the fullyhuman-
izedmonoclonal anti-CD20 antibody ofatumumab also dem-
onstrated efficacy in a phase 2 clinical study of patients with
RRMS.11
In a recently published Swedish study, the authors con-
cluded that treatment with rituximab was safe after a fol-
low-up of up to 2 years.12 Owing to the limited treatment op-
tions for SPMS and the extrapolation of results in RRMS and
PPMS, rituximabwasusedoff-label for the treatmentof SPMS.
The present retrospective cohort study uses propensity score
matching to compare disease progression between patients
whowere treatedwith rituximab and patientswhohadnever
been treated with rituximab.
Methods
PatientswithSPMS,definedaccording toestablishedcriteria,13
were eligible for this retrospective study if they had been
treated with rituximab off-label at the MS Centers in Basel or
Lugano, Switzerland; had received at least 1 dose of ritux-
imab; had had at least 1 clinical follow-up visit; and had pro-
vided informed consent (see Figure 1 for the study flow-
chart). Patients were treated with rituximab based on the
decision of the treating neurologist that the disease was pro-
gressive and that noother treatmentwas available. The study
was approvedby the local ethics committees of Lugano (comi-
tato etico cantonale, Bellinzona) and Basel (Ethikkommission
Nordwestschweiz und Zentralschweiz [EKNZ]) in Switzerland.
Informed consent was obtained inwritten (Lugano) or verbal
(by telephone interview, Basel) format.
In total, 54 rituximab-treated patients with SPMS were
compared with 59 patients with SPMS who had never been
treatedwith rituximab (control group) andwerepart of anob-
servationalcohort studyconductedat theMSCenterBasel,Uni-
versity of Basel, and theMS Center Amsterdam (at University
Medical Center Amsterdam, theNetherlands). That study, in-
cluding the informedconsentprocedure,was approvedby the
local ethics committees of Basel (EKNZ), and Amsterdam
(Medical Ethical Committee VUmc), and all patients pro-
vided written informed consent.
In a second step, the rituximab-treated and the control
groupswerematched 1:1 using propensity scores, resulting in
44matchedpatientpairs.Thematchingvariablesweresex,age,
ExpandedDisability StatusScale (EDSS) score, anddiseasedu-
ration at baseline.
For all patients, (at least) yearly standardized clinical as-
sessmentswereperformed, including a full neurologic exami-
nation (Neurostatus-EDSS). Inaddition, routinemagnetic reso-
nance imaging (MRI) findings for new T2 lesions and
gadolinium-enhancing lesionswere analyzed at baseline. Be-
causeMRIs at baselinewere available for only 33 patients (ap-
proximately 60% of the total cohort), MRI findings could not
beused for thematchingprocess.Magnetic resonance imaging
during follow-up was performed in only a minority of pa-
tients, and the images were therefore not analyzed for the
present study.
Main OutcomeMeasures
Theprimaryobjectiveof thepresent studywas tocomparedis-
ease progression as assessed by the EDSS score after baseline
Key Points
Question Does disability progression among patients with
secondary progressive multiple sclerosis treated with the
monoclonal anti-CD20 antibody rituximab differ from that among
such patients never treated with rituximab?
Findings In this cohort study of 88 propensity score–matched
patients, those treated with rituximab had a significantly lower
Expanded Disability Status Scale score for up to 10 years of
follow-up and significantly delayed confirmed progression
compared with matched controls. No associations between
confirmed progression and individual patient baseline
characteristics were identified.
Meaning Therapeutic options for patients with secondary
progressive multiple sclerosis are limited; however, these findings
suggest that B-cell–depleting therapymay be beneficial.
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inpatientswithSPMSwhoweretreatedwithrituximabvsthose
whowere not treatedwith rituximab. TheEDSS scorewas de-
termined annually for up to 10 years after baseline (Table 1).
Forpatients treatedwith rituximab,EDSS scores acquireddur-
ing treatment and for up to 1 year after the end of treatment
were analyzed.
One secondary objectivewas to analyze the time toCDP in
rituximab-treated patients with SPMS vs matched control pa-
tients.Confirmedprogressionwasdefinedasan increase in the
EDSS score 12 or more months after baseline, which was con-
firmedbyasecondexaminationconducted12months later.The
increasehad tobeat least 1.5 steps for anEDSSscoreof0, 1 step
for scores between 1 and 5, and 0.5 steps for scores of 5.5 or
greater.
The other secondary objective was to compare baseline
characteristics of patients in the rituximab-treatedgroupwith
confirmed progression with those of patients without con-
firmed progression in the same group.
Statistical Analysis
Aninitial comparisonofbaselinecharacteristics (age, sex,EDSS
score, anddiseaseduration)between the2groups showed that
patients treatedwith rituximabwere significantlyyounger and





pensity scores per cohort before and aftermatching are shown
ineFigure1intheSupplement.Standardizeddifferencesbetween
cohortsbeforeandafterpropensity scorematchingwerecalcu-
lated (eFigure 2 and eTable 1 in the Supplement).
Statistical analysiswasperformedusing the total cohort as
well asusing thematchedcohort.Althoughmatching improved
thebalance, considerabledifferences inbaselinecharacteristics
remainedbetweenthematchedgroups.Thus,all baselinechar-
acteristicswere includedascovariates in theanalysisof thetotal
cohort aswell as in theanalysis of thematchedcohort. Thepri-
mary end point, EDSS score after baseline,was analyzed using
alinearmixed-effectsmodeltoestimateeffectsizestogetherwith
95%CIs. To account formultiplemeasurements per patient, a
random intercept was added for each patient. As explanatory
variables, themodel included age, sex, disease duration, base-
line EDSS score, treatment (rituximab vs control), time after
baseline, and the interactionbetween treatmentand timeafter
baseline.All continuousexplanatoryvariables (age,diseasedu-
ration, and time after baseline) and baseline EDSS scores were
centered by subtracting the respectivemedian value for better
interpretation ofmodel intercepts.
We used a Bayesian approach to graphically display the
fittedvalues togetherwith their credible intervals (estimatedby
the correspondingmodel) for the primary end point. Posterior
distributions of the fitted values were calculated using the
simfunctioninthearmpackageofR.15Thefittedvaluesandcred-
ible intervals are displayed for a female “model patient” (the
presentdata set includedmorewomenthanmen)withmedian
valuesof thebaselineEDSSscore, baselineage, anddiseasedu-
ration (to represent the data set as accurately as possible).
Time to confirmed progression was analyzed as a sec-
ondary end point. Because there were 9 patients with 2 con-
firmed progression events (all in the control group), we used
recurrent event analysis by marginal means and rates mod-
els, allowing the accounting of multiple events per patient.
Age, sex, disease duration, baseline EDSS score, and treat-
ment were used as explanatory variables. A “cluster” term
in the model was used to compute a robust variance for the
model, accounting for nonindependent events from the
same patient. Moreover, we compared rituximab-treated
patients with or without confirmed progression regarding
baseline characteristics and rituximab treatments. Because
the number of rituximab-treated patients with confirmed
progression was small (n = 12), only bivariate associations
between confirmed progression and individual patient char-
acteristics were assessed. Associations between confirmed
progression and categorical variables (eg, sex) were
assessed using the Fisher exact test. Associations between
confirmed progression and continuous variables were
assessed using a Wilcoxon rank sum test.
All statistical analyses were performed with the
statistical softwareenvironmentR,version3.4.4 (RCoreTeam
2018).16 A 2-sided P < .05 was considered statistically
significant.
Results
Table 1 shows the baseline characteristics for 54 rituximab-
treated patients and 59 control patientswhowere not treated
Figure 1. Study Flowchart
561 Patients assessed 
for eligibility





















113 Patients included in analysis
88 Patients included in analysis 
after propensity score matching
EDSS indicates Expanded Disability Status Scale; SPMS, secondary progressive
multiple sclerosis.
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with rituximab before and after matching. Before matching,
patients from the rituximab groupwere significantly younger
andhadahighergradeofdisability.Aftermatching, therewere
no significantdifferencesbetween thegroups; however,Pval-
ues shouldbecomparedwithcautionbecausegroupsizeswere
reduced. At baseline after matching, patients treated with ri-
tuximab had a mean (SD) age of 49.7 (10.0) years, mean (SD)
diseasedurationof 18.2 (9.4) years, andmean (SD) EDSS score
of5.93 (1.40), and26 (59%)werewomen,whereascontrolshad
a mean (SD) age of 51.3 (7.4) years, mean (SD) disease dura-
tion of 19.4 (8.7) years, and a mean (SD) EDSS score of 5.70
(1.29), and27 (61%)werewomen.Standardizeddifferencesbe-
fore and aftermatching showed improved balance for the co-
variates EDSS score and age after matching (eFigure 2 and
eTable 1 in the Supplement). Analysis ofMRI findings at base-
line, whichwere not available for all patients (total rituximab
group, 33 [61%];matched rituximabgroup, 27 [61%]; total con-
trol group, 35 [59%]; matched control group, 23 [52%]), re-
vealed that 7 patients (26%) in the matched rituximab group
and0 patients in thematched control group had gadolinium-
enhancing lesions. Baseline MRIs for the matched rituximab
group were performed amean (SD) of 84.9 (57.8) days before
baseline (median, 77 days; range, 0-198 days), whereas base-
lineMRIs in the control groupwere performed at baseline. Of
8patients treatedwith rituximab (rituximab total group)with
anMRI finding of active disease at baseline, only 1 patient de-
veloped CDP during the study period. In the rituximab group
(matched cohort), 18 patients (41%)had receivedno immuno-
modulatory treatmentduring theyearbeforebaseline,whereas
in the control group, a slightly higher proportion (21 patients;
48%;) was untreated (for a detailed treatment summary see
eTable 2 in the Supplement).
Table 1. Baseline Characteristics and Follow-up Duration for the Total Cohort
Characteristica
Group Receiving Off-label
Rituximab Treatment Control Group P Valueb
Before propensity score matching
No. of patients 54 59
Age, y
Mean (SD) 49.0 (9.6) 53.5 (8.0)
.008
Median (range) 49.0 (23.0-71.0) 54.0 (37.0-70.0)
Female, No. (%) 32 (59) 33 (56) .85
Disease duration, y
Mean (SD) 18.6 (9.3) 18.8 (9.0)
.97
Median (range) 18.0 (3.0-40.0) 18.0 (3.0-45.0)
EDSS BL
Mean (SD) 6.02 (1.32) 5.21 (1.47)
.002
Median (range) 6.25 (2.50-8.50) 5.50 (2.00-8.00)
Follow-up, mo
Mean (SD) 42.3 (31.4) 64.3 (29.4)
<.001
Median (range) 33.9 (6.6-111.4) 59.9 (12.2-123.5)
Follow-up, y
Mean (SD) 3.5 (2.6) 5.4 (2.4)
Median (range) 2.8 (0.6-9.3) 5.0 (1.0-10.3)
After propensity score matching
No. of patients 44 44
Age, y
Mean (SD) 49.7 (10.0) 51.3 (7.4)
.36
Median (range) 50.0 (23.0-71.0) 50.5 (37.0-65.0)
Female, No. (%) 26 (59) 27 (61) >.99
Disease duration, y
Mean (SD) 18.2 (9.4) 19.4 (8.7)
.45
Median (range) 17.0 (3.0-40.0) 19.5 (3.0-35.0)
EDSS BL
Mean (SD) 5.93 (1.40) 5.70 (1.29)
.28
Median (range) 6.00 (2.50-8.50) 6.00 (2.50-8.00)
Follow-up, mo .
Mean (SD) 41.8 (32.2) 57.7 (26.5)
002
Median (range) 29.8 (6.6-111.4) 54.5 (12.2-112.3)
Follow-up, y
Mean (SD) 3.5 (2.7) 4.8 (2.2)
Median (range) 2.5 (0.6-9.3) 4.5 (1.0-9.4)
Abbreviation: EDSS BL, Expanded
Disability Status Scale score after
baseline.
a Number and percentage of patients
with measurements are given for
categorical variables; mean (SD) and
median (range) are given for
continuous and ordinal variables.
bDerived from Fisher exact tests
(categorical) and fromWilcoxon
rank sum tests (Mann-Whitney
tests, continuous). For standardized
differences between groups before
and after propensity score
matching, see eTable 1 in the
Supplement.
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The analysis of the primary end point showed that ritux-
imab treatment significantly reduced progression of disabil-
ity asmeasured by yearly EDSS scores for a follow-up of up to
10 years (mean [SD] follow-up, 3.5 [2.6] years) in the total pa-
tient cohort (estimate, −0.45; 95%CI, −0.71 to−0.20;P < .001)
aswell as in thematchedcohort (mean [SD] follow-up, 3.5 [2.7]
years; estimate, −0.52; 95% CI, −0.79 to −0.26; P < .001).
Figure 2 shows progression of EDSS scores over time for both
cohorts (total and matched) as estimated by the statistical
models.
With respect to the secondary end point, time to con-
firmed progressionwas significantly longer in the rituximab-
treatedgroupthan in thecontrolgroupfor the total cohort (haz-
ard ratio, 0.48; 95% CI, 0.26-0.91; P = .02) and the matched
cohort (hazard ratio,0.49;95%CI,0.26-0.93;P = .03).Figure3
shows the Kaplan-Meier plots for time to first confirmed
progression.
In the rituximab-treatedgroup, baseline characteristics as
well as number and dose of rituximab treatments for 12 pa-
tientswith or 42without progressionwere compared to iden-
tifypotential predictors for treatment response.Table2 shows
the categorical (sex and reason for rituximab) and continu-
ous (age, EDSS score at baseline, disease duration, number of
rituximab cycles, total cumulativedoseof administered ritux-
imab, duration of treatment, and treatment intensity) patient
characteristics for rituximab-treated patients with or with-
out confirmed progression. Patients with confirmed progres-
sionhadhigher cumulativedosesof rituximabandmore treat-
ment cyclesbut for a longerperiodof time; thus, the treatment
intensity (defined as the total amount of rituximab adminis-
tered in milligrams divided by the duration of treatment in
months) remainedsimilarcomparedwithpatientswithoutcon-
firmedprogression. In summary,noassociationsbetweencon-
firmedprogression and individual patient baseline character-
istics could be identified.
At the cutoff time for this analysis, 29of 54patients (54%)
were still being treated with rituximab with no complica-





















































































EDSS indicates Expanded Disability Status Scale.
























































Fitted values of the EDSS scores together with Bayesian 95% credible intervals 1
to 10 years after baseline for the total cohort (A) and thematched cohort (B).
The fitted values represent a female model patient of median age at baseline (A,
51 years; B, 50 years), median disease duration (A, 18 years; B, 18.5 years), and
with median baseline EDSS score (A, 6.0; B, 6.0). Median baseline EDSS score is
shown as a horizontal blue line. Themean treatment difference (during the
follow-up period) between rituximab and control of −0.45 (95% CI, −0.71 to
−0.20), estimated by the statistical model on the total set, can be read from
panel A at 5.5 years after baseline. Likewise, the mean treatment difference of
−0.52 (95% CI, −0.79 to −0.26) for thematched cohort can be read from panel
B.
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tions. In 5 cases (9%), complications were reported: 1 patient
had leukocytoclastic vasculitis in both legs (confirmed by bi-
opsy) after the first infusion (as reported previously17), 1 pa-
tient had a segmental herpes zoster infection, and 3 had 1 or
more pneumonia events or urinary tract infections.
Twopatients died during the follow-up period: 1 died of a
spontaneous intracerebral hemorrhage 3 years after stopping
rituximab treatment (rituximab therapy was stopped be-
cause the disease was stabilized), and 1 died of pneumonia 4
years after rituximab treatment had been stopped.
Discussion
To date, no prospective clinical trial has been performed to
evaluate theefficacyofB-celldepletion inSPMS.Themaingoal
of thepresent studywas to comparediseaseprogression inpa-
tientswith SPMS treatedwith rituximabwith that inmatched
control patients in a comprehensive real-world cohort. In the
rituximab group,weobserved a significant reduction of EDSS
scoreprogressionafterbaseline, thestudy’sprimaryendpoint.
This reduction in disability progression as assessed annually
by theEDSS score for up to 10yearswas significant in both the
total (mean follow-up, 3.5 years) and the propensity score–
matched (mean follow-up, 3.5 years) cohorts. The time to con-
firmedprogressionwas also significantly delayed in the ritux-
imab-treated group compared with the control group for the
total andmatched cohorts. These findings suggest that ritux-
imabadministrationmaybeassociatedwithabeneficial thera-
peutic effect in patients with SPMS.
Approximately 75% of untreated and 50% of treated
individuals in our cohorts developed clinically significant
confirmed progression for the 10-year period (Figure 3). This
is in line with other cohorts in which the rates of progression
during a 3- and a 10-year follow-up were 15% and 75%,
respectively.18-20





Confirmed Progression P Valueb
Categorical
No. of patients 12 42
Female, No. (%) 7 (58) 25 (60) >.99
Reason for rituximab, No. (%)
Progression 11 (92) 26 (62)
.16
Relapses 1 (8) 3 (7)
Progression and relapses 0 3 (7)
Other 0 0 (24)
Relapses under treatment, No. (%) 1 (8) 5 (12) >.99
Continuous
No. of patients 12 42
Age, y
Mean (SD) 49.7 (10.6) 48.8 (9.4)
.95
Median (range) 48.0 (33.0-71.0) 49.0 (23.0-70.0)
Disease duration, y
Mean (SD) 19.0 (10.6) 18.6 (9.0)
.83
Median (range) 19.5 (3.0-40.0) 18.0 (3.0-39.0)
Rituximab, No. of cycles
Mean (SD) 6.00 (2.09) 4.29 (2.99)
.04
Median (range) 6.50 (3.0-9.00) 3.50 (1.00-11.00)
Rituximab, cumulative dose, mg
Mean (SD) 9.54 (3.86) 6.00 (3.85)
.007
Median (range) 8.50 (5.00-15.00) 5.00 (1.00-16.00)
Rituximab, treatment duration, mo
Mean (SD) 60.9 (27.2) 42.1 (30.7)
.03
Median (range) 49.5 (32.0-110.0) 34.5 (6.0-107.0)
Rituximab, treatment intensity,
mg/moc
Mean (SD) 161.03 (32.10) 160.32 (50.85)
.88
Median (range) 156.05 (131.82-250.00) 160.26 (67.31-333.33)
Ordinal
EDSS BL
Mean (SD) 5.71 (1.41) 6.11 (1.30)
.35
Median (range) 6.00 (3.00-7.50) 6.50 (2.50-8.50)
Abbreviation: EDSS BL, Expanded
Disability Status Scale score after
baseline.
a Number and percentage of patients
with measurements are given for
categorical variables; mean (SD) and
median (range) are given for
continuous variables.
bDerived from Fisher exact tests
(categorical) and fromWilcoxon
rank sum tests (Mann-Whitney
tests, continuous).
c Defined as the total dose in
milligrams of rituximab
administered divided by the
duration of treatment in months.
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Thebaselinecharacteristicsofourpatientcohortclosely re-
sembled those of patients included in the recently completed
clinical trial examining the efficacy and safety of siponimod in
SPMS (EXPAND).21TheEXPANDstudyshowedasignificant re-
duction of disability progression in the treatment group com-
pared with that in the placebo group. The percentages of pa-
tientswitha6-monthCDPwere forplaceboandsiponimod28%
and 20% (year 2) and 30% and 23% (year 3), respectively. This
is comparable toaCDP in25%ofmatchedcontrols and in 12.5%
of rituximab-treatedpatients at year2and in37.5%ofmatched
controls and in 25% of rituximab-treated patients at year 3 in
our cohort. Another study looking at the efficacy of natali-
zumab for reducing disability progression in participants with
SPMS(ASCEND)22didnotmeet theprimaryendpointof reduc-
ingCDP. Ina retrospective,propensityscore–matchedcompari-
son of patients with SPMS from the MSBase registry who did
not show an effect of immunomodulatory treatment (mainly
interferonbetaandglatirameracetate,nopatients treatedwith
rituximab were included in the matched data set analysis) on
diseaseprogression, therateof6-monthconfirmeddiseasepro-
gression after 3 years was 23% (J.L., written communication,
September28, 2018).23These studies, alongwithour small ret-
rospective analysis, suggest that only a fewanti-inflammatory
treatmentsmaybe associatedwith a beneficial outcome inpa-
tientswithSPMS.All analyzedcompoundsdescribedabove in-
fluence B-cell biology albeit by different mechanisms of ac-
tion.Thedifferential response to these treatmentsmayprovide
clues to understanding which parts of the B-cell response are
pathogenic inSPMSandwhichpatientsmightbenefit fromsuch
treatments.
It is crucial to identify patient characteristics that indi-
cate a higher chance of treatment response. To identify po-
tential prognosticmarkers for therapeutic response, baseline
characteristics within the rituximab-treated group, compar-
ing patients with or without confirmed progression, were
tested. There was no significant difference in any tested cat-
egory. However, MRI scans were available in only 60% of pa-
tients; therefore, these results shouldbe interpretedwith cau-
tion. Of 8 patients treated with rituximab (rituximab total
group) with anMRI finding of active disease at baseline, only
1 patient developed CDP during the study period, whereas 12
of 54 patients in the rituximab total group showed CDP dur-
ing the present study. This might indicate that patients with
activedisease respondbetter to this kindof treatment. In gen-
eral, gadolinium-enhancing lesions at baseline are a risk fac-
tor for CDP in PPMS.10,24 The imbalance of increased MRI le-
sion activity in the rituximab group of our cohort might
therefore favor the control groupandunderestimate the treat-
ment effects associated with administration of rituximab.
WhetherMRI lesion activity is also associatedwith treatment
response must be evaluated in larger cohorts with standard-
ized MRI protocols.
There were no major safety concerns during the treat-
ment period, but complications were documented in 5 cases
(9.%), mainly related to infections.
Limitations
This study has some limitations. First, it was a retrospective
analysis of clinical data andnot aprospective, controlled, ran-
domized clinical trial. The present study design has a higher
risk of confounding the treatment effect associated with ri-
tuximabadministrationwithotherpatientdocumentedorun-
known characteristics and, as a consequence, a biased esti-
mate of the association. In fact, review of the baseline
characteristics indicated that patients in the rituximab group
tended to be younger, had a higher EDSS score, and showed
moreMRI lesion activity. It is conceivable that these patients
were more likely to be treated with rituximab.
In addition, that a higher proportion of the control pa-
tients had not been treated with disease-modifying treat-
ments in the year before baseline (49% and 48% in the total
andmatchedgroups, respectively, comparedwith39%and41%
of the rituximab-treated patients) could indicate a bias to-
ward a less aggressive disease course in the control group that
maycontribute tounderestimating theeffects associatedwith
administration of rituximab. Tomitigate confounding effects
of known disease characteristics, we used propensity score–
basedmatching in combinationwith covariate adjustment in
the statistical models. As shown by the standardized differ-
ences before and aftermatching, the differences between the
groupswere smaller after propensity scorematching. Further-
more, it was reassuring that the significant association ob-
served in the propensity score–matched comparisonwas also
significant in the total group analysis.
Conclusions
PatientswithSPMSwhowere treatedwith rituximabhada sig-
nificantly lower EDSS score up to 10 years after the initial as-
sessmentandsignificantlydelayedprogressioncomparedwith
patients with SPMS who had never been treated with ritux-
imab.Aprospective randomizedclinical trial isneeded toshow
efficacy in this patient group with a higher level of evidence.
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